Cosfarma Ltd

Cosfarma ltd, based in Harrow, UK, is a small, active company with a real registered address and a single director, Liutauras Alkinas, at the helm. Founded in 2023, it’s a relatively new venture, though it has a trading status. The company's description of principal activities is, however, missing from the report. It’s a filleted accounts company, meaning the full financial details aren's publicly available, and an audit exemption was granted.

The company's website, Cosfarma, appears to be inactive, and no e-commerce functionality is apparent. The report does not provide any information about the company's activities or products. It seems to be a limited operation.

Financially, Cosfarma ltd is facing significant challenges. Net assets have decreased substantially, from -£210,000 to -£270,000. Cash on hand has increased slightly, from £3,200 to £3,500, but bank borrowings have decreased considerably, from £20,000 to just £9,600. Creditors have also decreased, but the most striking change is the dramatic increase in debtors – rising from £7,800 to a staggering £52,000 within a year. This suggests a reliance on customer payments, or potentially, difficulties collecting debts. Loans from directors have ceased completely. Total inventories have also fallen, from £42,000 to £22,000.

The company's small size—meeting the criteria for turnover under £10.2m, assets under £5.1m, and fewer than 50 employees—allows it to remain agile. However, the negative equity and rising debtors are concerning. The accounts were prepared using FRS 102 Section 1A, and no auditor is mentioned, relying on unaudited statements. It's likely that the company is burning through money, and the sudden increase in debtors could be a sign of trouble ahead.

Registered in England/Wales under the registration number 09086009, with a registered address at HA1 1BH, United Kingdom, Harrow, 166 College Road.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.